DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ortho TRI-Cyclen (Norgestimate / Ethinyl Estradiol) - Published Studies


Published Studies Related to Ortho TRI-Cyclen (Norgestimate / Ethinyl Estradiol)

Well-designed clinical trials related to Ortho TRI-Cyclen (Norgestimate / Ethinyl Estradiol)

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. [2011.04]

Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women. [2009.11]

Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. [2006.12]

Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study. [2005.09]

Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. [2004.08]

Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. [2003.08]

Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. [2003.07]

Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. [2003.06]

Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women. [2002.12]

The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol. [2002.09]

Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. [2002.02]

Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. [2001.06]

Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. [2000.12]

Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. [1999.03]

The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. [1998.11]

Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. [1998.08]

The tolerability of a triphasic norgestimate/EE-containing OC: results from a double-blind, placebo-controlled trial. [1998.07.01]

Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. [1997.11]

Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. [1997.04]

Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open, randomized, parallel-group study. [1995.09]

Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. [1995.06]

Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. [1995]

Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. [1994.03]

Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol. [1993.12]

A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. [1992]

Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. [1992]

Clinical evidence of the minimal androgenic activity of norgestimate. [1989.09]

Well-designed clinical trials possibly related to Ortho TRI-Cyclen (Norgestimate / Ethinyl Estradiol)

Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. [2011.08]

Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. [2011]

Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. [2009.12]

Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. [2009.08]

Effect of oral versus transdermal steroidal contraceptives on androgenic markers. [2005.06]

Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. [2005.03]

Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]

Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. [2003.03]

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. [2003.03]

Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. [2003.01]

The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne. [2002.10]

Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. [2002.01]

Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. [2001.11]

A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. [2001.07]

Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. [1999.12]

Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. [1999.12]

Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. [1999.08]

Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. [1996.11]

Changes in androgens during treatment with four low-dose contraceptives. [1996.03]

Ovarian function during low-dose oral contraceptive use. [1995.06]

Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives. [1995]

Long-term profile of a new progestin. [1992]

[Side effects of oral contraceptives in the first treatment cycle] [1991]

Other research related to Ortho TRI-Cyclen (Norgestimate / Ethinyl Estradiol)

Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A. [2011.04]

The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. [2011]

[Occurrence of bleeding in women using combined hormonal contraceptives (ethinylestradiol 35 micrograms/norgestimate 250 micrograms in relation to regularity of administration and cycle start day] [2003.03]

Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. [2003.02]

Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study. [2003]

Pharmacokinetic overview of Ortho Evra/Evra. [2002.02]

[Liver function tests during administration of triphasic contraceptives containing Norgestimate] [2000.11]

[Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women] [1999.07]

Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. [1994.05]

A norgestimate-containing oral contraceptive: review of clinical studies. [1992.10]

The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women. [1992.06]

Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. [1992]

Clinical experience with a new norgestimate-containing oral contraceptive. [1992]

Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol. [1992]

Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. [1992]

Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. [1992]

[Acceptance and subjective well-being with a norgestimate combination pill] [1991]

Clinical experience with a new norgestimate-containing oral contraceptive. [1991]

[Clinical evidence of the minimal androgenic activity of norgestimate] [1990.06]

Supportive European data on a new oral contraceptive containing norgestimate. [1990]

Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials. [1990]

Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol. [1978.03]

Other possibly related research studies

The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. [2004.03]

Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated cooperstown 5+1 cocktail. [2005.12]

Hormonal treatment of acne: review of current best evidence. [2004]

The role of combined oral contraceptives in the management of acne and seborrhea. [2004.06]

Enhancing oral contraceptive success: the potential of new formulations. [2004.04]

Rationale for new oral contraceptive dosing. [2004.01]

Update and future of systemic acne treatment. [2003]

Contraceptives and cerebral thrombosis: a five-year national case-control study. [2002.03]

Triphasic oral contraceptives: review and comparison of various regimens. [2002.01]

Transdermal contraception. [2001.12]

[Results from the Registry of Complications in Users of Hormonal Contraception in 1998] [2000.03]

Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. [2000.04]

Is there an increased risk of stroke associated with oral contraceptives? [1999.06]

Oral contraceptive health benefits: perception versus reality. [1999.01]

Altered reflex control of cutaneous circulation by female sex steroids is independent of prostaglandins. [1999.05]

[Current monophasic hormonal contraception] [1998]

[Rationale for prescribing oral contraceptives] [1998]

The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. [1997.03]

Cerebral thrombosis and oral contraceptives. A case-control study. [1998.05]

Effect of oral contraceptives on haemostasis variables. [1997.07]

Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism. [1997.05]

Estrogen and progestin components of oral contraceptives: relationship to vascular disease. [1997.05]

Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. [1996.08]

No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. [1996.07]

Biochemical effects in women following one year's exposure to a new triphasic contraceptive--II. coagulation profiles. [1996.03]

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. [1995.12.16]

[Pharmacology of oral contraceptives] [1995.12.01]

[Clinical effectiveness of Marvelon] [1995.05]

European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12". [1995]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017